Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides

Tammy Price-Troska, Zhi Zhang Yang, David Diller, Alexander Bayden, Mark Jarosinski, Joseph Audie, Stephen Maxted Ansell

Research output: Contribution to journalArticle

Abstract

Summary: Background Increased serum levels of soluble interleukin-2 (IL-2) receptor alpha (sIL-2Rα) are an indicator of poor prognosis in patients with B-cell non-Hodgkin lymphoma (NHL). By binding to IL-2, sIL-2Rα upregulates Foxp3 expression and induces the development of regulatory T (Treg) cells. Methods To inhibit the binding of IL-2 to sIL-2Rα with the goal of suppressing the induction of Foxp3 and decreasing Treg cell numbers, we developed peptides by structure-based computational design to disrupt the interaction between IL-2 and sIL-2Rα. Each peptide was screened using an enzyme-linked immunosorbent assay (ELISA), and 10 of 22 peptides showed variable capacity to inhibit IL-2/sIL-2Rα binding. Results We identified a lead candidate peptide, CMD178, which consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/sIL-2Rα signaling. Furthermore, production of cytokines (IL-2/interferon gamma [IFN-γ]) and granules (perforin/granzyme B) was preserved in CD8+ T cells co-cultured with IL-2–stimulated CD4+ T cells that had been pretreated with CMD178 compared to CD8+ cells co-cultured with untreated IL-2–stimulated CD4+ T cells where it was inhibited. Conclusions We conclude that structure-based peptide design can be used to identify novel peptide inhibitors that block IL-2/sIL-2Rα signaling and inhibit Treg cell development. We anticipate that these peptides will have therapeutic potential in B-cell NHL and other malignancies.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalInvestigational New Drugs
DOIs
StateAccepted/In press - Apr 26 2018

Fingerprint

Regulatory T-Lymphocytes
Interleukin-2
Peptides
B-Cell Lymphoma
T-Lymphocytes
Non-Hodgkin's Lymphoma
Interleukin-2 Receptor alpha Subunit
Interferon-gamma
Cultured Cells
Up-Regulation
Cell Count
Enzyme-Linked Immunosorbent Assay
Cytokines
Serum
Neoplasms

Keywords

  • Computationally designed peptides
  • Foxp3
  • Soluble IL-2Ra
  • STAT5
  • T cells

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides. / Price-Troska, Tammy; Yang, Zhi Zhang; Diller, David; Bayden, Alexander; Jarosinski, Mark; Audie, Joseph; Ansell, Stephen Maxted.

In: Investigational New Drugs, 26.04.2018, p. 1-8.

Research output: Contribution to journalArticle

Price-Troska, Tammy ; Yang, Zhi Zhang ; Diller, David ; Bayden, Alexander ; Jarosinski, Mark ; Audie, Joseph ; Ansell, Stephen Maxted. / Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides. In: Investigational New Drugs. 2018 ; pp. 1-8.
@article{3abe405f57314d9282a5d787070d83ad,
title = "Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides",
abstract = "Summary: Background Increased serum levels of soluble interleukin-2 (IL-2) receptor alpha (sIL-2Rα) are an indicator of poor prognosis in patients with B-cell non-Hodgkin lymphoma (NHL). By binding to IL-2, sIL-2Rα upregulates Foxp3 expression and induces the development of regulatory T (Treg) cells. Methods To inhibit the binding of IL-2 to sIL-2Rα with the goal of suppressing the induction of Foxp3 and decreasing Treg cell numbers, we developed peptides by structure-based computational design to disrupt the interaction between IL-2 and sIL-2Rα. Each peptide was screened using an enzyme-linked immunosorbent assay (ELISA), and 10 of 22 peptides showed variable capacity to inhibit IL-2/sIL-2Rα binding. Results We identified a lead candidate peptide, CMD178, which consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/sIL-2Rα signaling. Furthermore, production of cytokines (IL-2/interferon gamma [IFN-γ]) and granules (perforin/granzyme B) was preserved in CD8+ T cells co-cultured with IL-2–stimulated CD4+ T cells that had been pretreated with CMD178 compared to CD8+ cells co-cultured with untreated IL-2–stimulated CD4+ T cells where it was inhibited. Conclusions We conclude that structure-based peptide design can be used to identify novel peptide inhibitors that block IL-2/sIL-2Rα signaling and inhibit Treg cell development. We anticipate that these peptides will have therapeutic potential in B-cell NHL and other malignancies.",
keywords = "Computationally designed peptides, Foxp3, Soluble IL-2Ra, STAT5, T cells",
author = "Tammy Price-Troska and Yang, {Zhi Zhang} and David Diller and Alexander Bayden and Mark Jarosinski and Joseph Audie and Ansell, {Stephen Maxted}",
year = "2018",
month = "4",
day = "26",
doi = "10.1007/s10637-018-0606-9",
language = "English (US)",
pages = "1--8",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides

AU - Price-Troska, Tammy

AU - Yang, Zhi Zhang

AU - Diller, David

AU - Bayden, Alexander

AU - Jarosinski, Mark

AU - Audie, Joseph

AU - Ansell, Stephen Maxted

PY - 2018/4/26

Y1 - 2018/4/26

N2 - Summary: Background Increased serum levels of soluble interleukin-2 (IL-2) receptor alpha (sIL-2Rα) are an indicator of poor prognosis in patients with B-cell non-Hodgkin lymphoma (NHL). By binding to IL-2, sIL-2Rα upregulates Foxp3 expression and induces the development of regulatory T (Treg) cells. Methods To inhibit the binding of IL-2 to sIL-2Rα with the goal of suppressing the induction of Foxp3 and decreasing Treg cell numbers, we developed peptides by structure-based computational design to disrupt the interaction between IL-2 and sIL-2Rα. Each peptide was screened using an enzyme-linked immunosorbent assay (ELISA), and 10 of 22 peptides showed variable capacity to inhibit IL-2/sIL-2Rα binding. Results We identified a lead candidate peptide, CMD178, which consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/sIL-2Rα signaling. Furthermore, production of cytokines (IL-2/interferon gamma [IFN-γ]) and granules (perforin/granzyme B) was preserved in CD8+ T cells co-cultured with IL-2–stimulated CD4+ T cells that had been pretreated with CMD178 compared to CD8+ cells co-cultured with untreated IL-2–stimulated CD4+ T cells where it was inhibited. Conclusions We conclude that structure-based peptide design can be used to identify novel peptide inhibitors that block IL-2/sIL-2Rα signaling and inhibit Treg cell development. We anticipate that these peptides will have therapeutic potential in B-cell NHL and other malignancies.

AB - Summary: Background Increased serum levels of soluble interleukin-2 (IL-2) receptor alpha (sIL-2Rα) are an indicator of poor prognosis in patients with B-cell non-Hodgkin lymphoma (NHL). By binding to IL-2, sIL-2Rα upregulates Foxp3 expression and induces the development of regulatory T (Treg) cells. Methods To inhibit the binding of IL-2 to sIL-2Rα with the goal of suppressing the induction of Foxp3 and decreasing Treg cell numbers, we developed peptides by structure-based computational design to disrupt the interaction between IL-2 and sIL-2Rα. Each peptide was screened using an enzyme-linked immunosorbent assay (ELISA), and 10 of 22 peptides showed variable capacity to inhibit IL-2/sIL-2Rα binding. Results We identified a lead candidate peptide, CMD178, which consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/sIL-2Rα signaling. Furthermore, production of cytokines (IL-2/interferon gamma [IFN-γ]) and granules (perforin/granzyme B) was preserved in CD8+ T cells co-cultured with IL-2–stimulated CD4+ T cells that had been pretreated with CMD178 compared to CD8+ cells co-cultured with untreated IL-2–stimulated CD4+ T cells where it was inhibited. Conclusions We conclude that structure-based peptide design can be used to identify novel peptide inhibitors that block IL-2/sIL-2Rα signaling and inhibit Treg cell development. We anticipate that these peptides will have therapeutic potential in B-cell NHL and other malignancies.

KW - Computationally designed peptides

KW - Foxp3

KW - Soluble IL-2Ra

KW - STAT5

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=85046029369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046029369&partnerID=8YFLogxK

U2 - 10.1007/s10637-018-0606-9

DO - 10.1007/s10637-018-0606-9

M3 - Article

C2 - 29696509

AN - SCOPUS:85046029369

SP - 1

EP - 8

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

ER -